Page last updated: 2024-12-11
4'-methylene-5,8,10-trideazaaminopterin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4'-methylene-5,8,10-trideazaaminopterin: an antirheumatic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9846537 |
| CHEMBL ID | 4802141 |
| SCHEMBL ID | 7281 |
| MeSH ID | M0500513 |
Synonyms (19)
| Synonym |
|---|
| SCHEMBL7281 |
| 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid |
| ch 1504 |
| unii-8y3rh62xpb |
| mobiletrex |
| 4'-methylene-5,8,10-trideazaaminopterin |
| 238074-89-0 |
| 8y3rh62xpb , |
| ch-1504 |
| m-trex |
| DB05616 |
| CHEMBL4802141 |
| 2-(4-(2-(2,4-diaminoquinazolin-6-yl)ethyl)benzamido)-4-methylenepentanedioic acid |
| 2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid |
| glutamic acid, n-(4-(2-(2,4-diamino-6-quinazolinyl)ethyl)benzoyl)-4-methylene- |
| tridam |
| aa-243 |
| 2-((4-(2-(2,4-diaminoquinazolin-6-yl)ethyl)benzoyl)amino)-4-methylene-pentanedioic acid |
| AKOS040748126 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events across treatment groups were mild." | ( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011) | 0.37 |
| "CH-1504 has comparable efficacy to MTX and is safe and well tolerated." | ( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011) | 0.37 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted." | ( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects. Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008) | 0.35 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted." | ( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects. Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008) | 0.35 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " No dose-response relationship was observed." | ( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.07) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (50.00%) | 5.53% |
| Reviews | 2 (33.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (16.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||